Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Abstract Background The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epitheli...

Full description

Bibliographic Details
Main Authors: Vincenza Conteduca, Giorgia Gurioli, Lorena Rossi, Emanuela Scarpi, Cristian Lolli, Giuseppe Schepisi, Alberto Farolfi, Delia De Lisi, Valentina Gallà, Salvatore Luca Burgio, Cecilia Menna, Andrea Amadori, Lorena Losi, Dino Amadori, Maria Paola Costi, Ugo De Giorgi
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
FOLFOX-4
Fluorouracil
Topotecan
Ovarian cancer
Platinum resistance
Survival
Online Access:http://link.springer.com/article/10.1186/s12885-018-5180-1

Internet

http://link.springer.com/article/10.1186/s12885-018-5180-1

Similar Items